Market segmentation based on product offerings:
Based on product offerings, the HCM market is segmented into eight types of solutions – core human resources (HR), payroll and compensation management, performance management, learning, talent acquisition, workforce management, benefits administration, and other solutions. The learning management segment is expected to witness the highest growth, expanding at a CAGR of ~12.67%.
The performance management and talent acquisition solution segments are likely to experience rapid growth during the 2020-2025 period.
Market segmentation based on component and deployment type:
In FY 2019, based on components, the HCM software market accounted for 66.86% of the overall market revenue. The HCM services segment accounted for ~34.14% of the total market share in the same financial year.
Based on deployment type, the HCM market in India is segmented into Cloud and on-premises solutions. During the forecast period, the market share of the on-premises solutions segment is anticipated to decline on account of limitations associated with storage space on local servers. In FY 2019, the Cloud-based HCM services segment accounted for ~79% of the overall market size, which is likely to go up substantially by the end of 2025.

Market segmentation based on industry vertical:
Key industries served by the Indian HCM solutions market include banking, financial services, and insurance (BFSI), consumer goods and retail, telecom and IT, manufacturing, and healthcare. The consumer goods and retail industry accounted for the highest share in FY 2019, taking up ~14.96% of the total market size, followed closely by telecom and IT. The government sector and manufacturing sector’s market share is estimated to experience significant growth during the forecast period.
Impact of COVID-19:
The COVID-19 outbreak has led to unprecedented economic turmoil across the world, and India’s human capital management market is not expected to be resilient to its impact. Due to the pandemic, the way organizations manage and communicate with employees has experienced a drastic change. Companies have been forced to make changes in their existing HCM solutions. Organizations that had not yet made the big switch by digitalizing their internal processes had to adopt online working environments to run their businesses smoothly during the crisis. Overall, the HCM market in the country and all over the world has experienced a definite growth curve amid the pandemic.

Market influencers:
HCM solutions allow organizations to use intuitive training to engage and educate their employees, bridging the skill gap. Further, organizations are enabled to create a pipeline of talent ensuring leadership continuity. HCM solutions also provide application tracking software to make the entire recruitment process seamless and error-free. Along with these perks, they optimize workforce engagement and allow better resource allocation.
Moreover, artificial intelligence (AI) and machine learning (ML) are being widely adopted by organizations across the country to improve their HCM practices. Companies are switching to a mobile-responsive design of HCM software to allow better user engagement, enhanced performance and reduced device management costs.
Competitive landscape:
The human capital management market in India is led by a balanced mix of established players, and numerous mid-level, emerging and small players. Companies like ADP India Pvt. Ltd, Oracle India Pvt. Ltd. and SAP India Pvt. Ltd. are key players in the market.

Companies covered:
• ADP India Pvt. Ltd.
• Beehive Software Services Pvt. Ltd.
• FlexiEle Consulting Services Pvt. Ltd.
• Greytip Software Pvt. Ltd.
• Oracle India Pvt. Ltd.
• SAP India Pvt. Ltd.
• Spine Technologies India Pvt. Ltd.
• Uneecops Workplace Solutions Pvt. Ltd
• ZingHR Techno India Pvt. Ltd.
• Zoho Corporation Pvt. Ltd.

The post Human Capital Management Market in India 2020 first appeared on CRI Report.

The post Organic Personal Care Products Market in India 2019 first appeared on CRI Report.

Market segment insights:
Based on sales channel, the Indian frozen food market is segmented into retailers, food service providers and export. In 2019, the export segment held ~47.64% of the total market revenue. The frozen food export was the leading sales segment in 2019 contributing to ~47.64% of the total market revenue during the year. This segment is anticipated to dominate till the end of 2024, as the demand for food continues to rise globally.
Retailer segment is expected to be the fast-growing segment, expanding at a CAGR of 21.44% during the forecast period and is expected to account for ~22.78% of the frozen food market revenue by 2024. The rising popularity of convenience foods including frozen vegetables, frozen meat and frozen snacks among working women, millennials, and Gen-Z consumers is expected to push retailers to increase their storage capacity of frozen foods. Moreover, surge in smartphone usage and increased penetration of the Internet have created opportunities for online grocery stores like BigBasket, Amazon and Grofers to enter the frozen food market in India.

Market competition:
Owing to stringent regulations in terms of food safety and higher capital requirements for building reliable infrastructure to store frozen foods, the threat of new entrants remains low in this market. Moreover, presence of established players like ITC, McCain Foods, Mother Dairy and Godrej Yummiez has further increased the entry barrier for the new players to establish their businesses.
However, the intensity of rivalry among established players is very high. Frozen food products are mostly undifferentiated, and hence market players compete in terms of pricing and brand loyalty.
Companies covered
• Apex Frozen Foods Ltd.
• Godrej Agrovet Ltd.
• ITC Ltd.
• Venky’s (India) Ltd.
• Capricorn Food Products India Ltd.
• HyFun Frozen Foods Pvt. Ltd.
• Innovative Foods Ltd.
• Mother Dairy Fruit and Vegetable Pvt. Ltd.
• Top Fresh International Pvt. Ltd.
• McCain Foods (India) Pvt. Ltd.

The post Frozen Foods Market in India 2020 first appeared on CRI Report.

The pharmacy retail market in India has witnessed significant growth over the past few years, owing to favourable demographic factors and an epidemiological transition. In terms of revenue, the pharmacy retail market in India was valued at INR 996.68 Bn in 2016 and is projected to reach INR 2,330.20 Bn by 2024, expanding at a CAGR of 10.08% during the 2019-2024 period.

The market is majorly occupied by unorganized local players. However, the unorganized sector is anticipated to face intense competition from organized players and online retailers.

Market segmentation based on retail channel:
Based on the retail channel, the market is segmented into organized sector, unorganized sector, and online retail. The unorganized sector accounted for the largest market share (~93.00%) in 2018.

The market share of the organized sector, which consists of licensed and registered players, is estimated to increase steadily over the forecast period.

The online retail segment is projected to expand at a CAGR of ~33.95% during the 2019-2024 period, owing to strong digital infrastructure in the country.

Market segmentation based on drug type:
The generic drugs segment dominated the retail pharmacy market in India, followed by the OTC drugs and patented drugs segments. The low price of generic drugs attributed to its leading share.

The OTC drugs segment is predicted to be the second-leading segment of the pharmacy retail market with a share of ~22.40% in 2024. The inclusion of various medicines under the OTC category, coupled with a preference towards self-medication is predicted to drive the growth of the OTC drugs segment.

The market share of the patented drugs segment is estimated to increase by 5.4% from 2018 to 2024, owing to the launch of various patented drugs in the Indian market.

Market segmentation based on therapeutic area:
In terms of revenue, anti-infectives was the largest therapeutic segment of the India pharmacy retail market in 2018, followed by the cardiac, gastrointestinal, and anti-diabetic segments. The cardiac therapeutic segment is estimated to surpass the anti-infectives segment during the forecast period.

The cardiac segment is anticipated to account for a share of ~14.11% in 2024. The changing disease profile in the country and increasing cases of chronic non-communicable diseases are anticipated to contribute to the growth of cardiac, anti-diabetic, dermatological, and neurological therapeutic segments.

Market influencers:
Increased affordability, improved accessibility and epidemiological transition are expected to fuel the pharmacy retail market in India during the forecast period. The rise in per capita income and penetration of health insurance coverage has bolstered Indian consumers’ affordability. A significant increase in the number of Indians covered under health insurance has helped propel consumer spending on pharmaceuticals.

With the rise in public healthcare expenditure, pharmaceuticals have become more accessible, thereby fueling the pharmacy retail market, especially in rural areas and tier-II cities. Furthermore, the launch of various patented drugs by international pharmaceutical companies resulted in an incremental increase in pharmaceutical sales.

The growing incidence of chronic diseases like hypertension, diabetes, cardiovascular diseases, and cancer, which requires prolonged medication, is expected to further drive the growth of the pharmacy retail market in India during the forecast period.

The sluggish economic growth in the country, owing to factors like agrarian crisis, retail inflation, and lack of fiscal stimulants, have had a negative impact on the profitability of the pharmacy retail market. Index of industrial production (IIP) growth rate of the pharmaceutical industry has experienced a declining trend; the growth rate declined from 30.4% in FY 2017 to 1.6% in FY 2019.

Furthermore, uncertainty in drug pricing has posed a substantial challenge in the pharmacy retail market by way of affecting investors’ sentiments. The implementation of GST has further burdened pharmacy retailers with a low inventory stock and consequent reductions in profitability.

Emergence of online retailers
The e-pharmacy market in India has evolved from its nascent stage to a promising market with strong growth potential. The influx of investments and a rise in Internet subscribers have helped shape up the e-pharmacy market in the country. Online players like Netmeds, 1mg, PharmEasy and MedLife have recently emerged in the Indian pharmacy retail market.

Along with core online players, various traditional offline companies have expanded their retail operations in the online platform to offer value-added services to customers.

Companies covered
• Apollo Pharmacies Limited
• Emami Frank Ross Limited
• Global Healthline Private Limited
• Medlife
• MedPlus Health Services Private Limited
• Netmeds Marketplace Limited
• Noble Medichem Pvt Ltd. (Noble Plus)
• RWL Healthworld Limited (Fortis Health World)
• Wellness Forever Pharmacy
• 91Streets Media Technologies Private Limited (PharmEasy)

Pharmacy Retail Market in India 2020

The post Pharmacy Retail Market in India 2019 first appeared on CRI Report.

Market Overview

The Egypt honey market is expected to register notable growth during the forecast period. Some of the key factors fueling the growth of the Egypt honey market are the health benefits associated with honey and a growing preference for natural sweeteners among consumers. Furthermore, advancements in honey production technology and rising consumer preference for organic products are expected to create lucrative opportunities for players operating in the Egyptian market during the forecast period. However, honeybee losses and fluctuating prices of honey act as a restraint to market growth.

Honey is a naturally sweet liquid produced by bees and is extracted through a plant’s nectar. More than a sweetener, honey also carries numerous health benefits and has gained popularity in many industrial applications. The major components of honey include carbohydrates, water, nitrogenous substances, and minerals.

The Egypt honey market is expected to register a notable growth rate during the forecast period. Health benefits associated with honey are mainly driving the growth of the market. Growing preference for healthy sweeteners among consumers is further supporting the market growth. Furthermore, advancements in honey production technology and rising consumer preference for organic products are some of the factors expected to present new opportunities for the vendors active in the Egypt honey market. However, honeybee losses and fluctuating honey prices are restricting the growth of the honey market. Additionally, honey laundering practices present challenging situations for market growth.

Market Segmentation

Based on type, the Egypt honey market has been segmented into clover honey, citrus honey, cotton honey, wildflower honey, and others. Based on category, the Egypt honey market has been segmented into organic and conventional. sBased on application, the Egypt honey market has been segmented into food & beverages, personal care products, pharmaceuticals, and others.

Major Players

The key players operating in the Egypt honey market include Dabur Egypt Ltd (Egypt), Ahla Honey (Egypt), Imtenan (Egypt), Sunbulah Group (Saudi Arabia), ISIS For Food Industries (Egypt), Elnada Bee (Egypt), El Rashidi El Mizan Confectionery (Egypt), Alwefak Al-Saudi for Food Industries (Egypt), Mahmoud Gomaa Abd El Galil Co (Egypt), and Mudga Agriculture & Food Products Suppliers (Egypt).

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY
1.1 EGYPT HONEY MARKET, BY TYPE
1.2 EGYPT HONEY MARKET, BY CATEGORY
1.3 EGYPT HONEY MARKET, BY APPLICATION

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 KEY BUYING CRITERIA

3 RESEARCH METHODOLOGY
3.1 RESEARCH PROCESS
3.2 PRIMARY RESEARCH
3.3 SECONDARY RESEARCH
3.4 MARKET SIZE ESTIMATION
3.5 FORECAST MODEL
3.6 LIST OF ASSUMPTIONS

4 MARKET DYNAMICS
4.1 INTRODUCTION
4.2 DRIVERS
4.2.1 HEALTH BENEFITS ASSOCIATED WITH HONEY
4.2.2 CONSUMER PREFERENCE FOR HEALTHY SWEETENERS
4.2.3 DRIVERS IMPACT ANALYSIS
4.3 RESTRAINTS
4.3.1 4. HONEYBEE LOSSES
4.3.2 5. FLUCTUATION IN THE PRICES OF HONEY
4.3.3 RESTRAINTS IMPACT ANALYSIS
4.4 OPPORTUNITIES
4.4.1 RISING CONSUMER PREFERENCE FOR ORGANIC HONEY
4.4.2 ADVANCEMENTS IN HONEY HARVESTING TECHNOLOGY
4.5 CHALLENGES
4.5.1 HONEY LAUNDERING

5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.2 SUPPLY CHAIN ANALYSIS
5.3 PORTER’S FIVE FORCES MODEL
5.3.1 THREAT OF NEW ENTRANTS
5.3.2 BARGAINING POWER OF SUPPLIERS
5.3.3 THREAT OF SUBSTITUTES
5.3.4 BARGAINING POWER OF BUYERS
5.3.5 INTENSITY OF RIVALRY
5.4 IMPACT OF COVID-19 OUTBREAK ON THE EGYPT HONEY MARKET
5.4.1 OVERVIEW
5.4.2 IMPACT ON PRODUCTION
5.4.3 IMPACT ON SUPPLY CHAIN
5.4.4 IMPACT ON PRICING
5.4.5 IMPACT ON CONSUMER BUYING BEHAVIOR

6 EGYPT HONEY MARKET, PRODUCTION AND TRADE ANALYSIS
6.1 EGYPT HONEY MARKET- PRODUCTION ANALYSIS (2020)
6.2 EGYPT HONEY MARKET- DOMESTIC TRADE (2020)
6.3 EGYPT HONEY MARKET- EXPORT ANALYSIS (2020)
6.4 EGYPT HONEY MARKET- IMPORT ANALYSIS (2020)

7 EGYPT HONEY MARKET, BY TYPE
7.1 OVERVIEW
7.2 CLOVER HONEY
7.3 CITRUS HONEY
7.4 COTTON HONEY
7.5 WILDFLOWER HONEY
7.6 OTHERS
7.6.1 EGYPT HONEY MARKET ESTIMATES & FORECAST, BY TYPE, 2019–2028

8 EGYPT HONEY MARKET, BY CATEGORY
8.1 OVERVIEW
8.2 ORGANIC
8.3 CONVENTIONAL
8.3.1 EGYPT HONEY MARKET ESTIMATES & FORECAST, BY CATEGORY, 2019–2028

9 EGYPT HONEY MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 FOOD & BEVERAGES
9.3 PERSONAL CARE PRODUCTS
9.4 PHARMACEUTICALS
9.5 OTHERS
9.5.1 EGYPT HONEY MARKET ESTIMATES & FORECAST, BY APPLICATION, 2019–2028

10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.1.1 MARKET STRATEGY ANALYSIS
10.2 COMPETITIVE BENCHMARKING

11 COMPANY PROFILES
11.1 DABUR EGYPT LTD
11.1.1 COMPANY OVERVIEW
11.1.2 FINANCIAL OVERVIEW
11.1.3 PRODUCTS OFFERED
11.1.4 KEY DEVELOPMENTS
11.1.5 SWOT ANALYSIS
11.1.6 KEY STRATEGIES
11.2 AHLA HONEY
11.2.1 COMPANY OVERVIEW
11.2.2 FINANCIAL OVERVIEW
11.2.3 PRODUCTS/SERVICES OFFERED
11.2.4 KEY DEVELOPMENTS
11.2.5 SWOT ANALYSIS
11.2.6 KEY STRATEGIES
11.3 IMTENAN
11.3.1 COMPANY OVERVIEW
11.3.2 FINANCIAL OVERVIEW
11.3.3 PRODUCTS OFFERED
11.3.4 KEY DEVELOPMENTS
11.3.5 SWOT ANALYSIS
11.3.6 KEY STRATEGIES
11.4 SUNBULAH GROUP
11.4.1 COMPANY OVERVIEW
11.4.2 FINANCIAL OVERVIEW
11.4.3 PRODUCTS OFFERED
11.4.4 KEY DEVELOPMENTS
11.4.5 SWOT ANALYSIS
11.4.6 KEY STRATEGIES
11.5.1 COMPANY OVERVIEW
11.5.2 FINANCIAL OVERVIEW
11.5.3 PRODUCTS OFFERED
11.5.4 KEY DEVELOPMENTS
11.5.5 SWOT ANALYSIS
11.5.6 KEY STRATEGIES
11.6 ELNADA BEE
11.6.1 COMPANY OVERVIEW
11.6.2 FINANCIAL OVERVIEW
11.6.3 PRODUCTS OFFERED
11.6.4 KEY DEVELOPMENTS
11.6.5 KEY STRATEGIES
11.7 EL RASHIDI EL MIZAN CONFECTIONERY
11.7.1 COMPANY OVERVIEW
11.7.2 FINANCIAL OVERVIEW
11.7.3 PRODUCTS OFFERED
11.8 ALWEFAK AL-SAUDI FOR FOOD INDUSTRIES
11.8.1 COMPANY OVERVIEW
11.8.2 FINANCIAL OVERVIEW
11.8.3 PRODUCTS OFFERED
11.8.4 KEY DEVELOPMENTS
11.8.5 KEY STRATEGIES
11.9 MAHMOUD GOMAA ABD EL GALIL CO
11.9.1 COMPANY OVERVIEW
11.9.2 FINANCIAL OVERVIEW
11.9.3 PRODUCTS OFFERED
11.9.4 KEY DEVELOPMENTS
11.9.5 KEY STRATEGIES
11.10 MUDGA AGRICULTURE & FOOD PRODUCTS SUPPLIERS
11.10.1 COMPANY OVERVIEW
11.10.2 FINANCIAL OVERVIEW
11.10.3 PRODUCTS OFFERED
11.10.4 KEY DEVELOPMENTS
11.10.5 KEY STRATEGIES

12 REFERENCES

The post Egypt Honey Market Research Report Forecast to 2028 first appeared on CRI Report.

The total mitochondrial myopathy diagnosis and treatment market is expected to reach USD 33.6 million by 2020 at a CAGR of 9.82% during the forecast period.
The global mitochondrial myopathy diagnosis and treatment market by types is segmented into mitochondrial encephalomyopathy, lactic acidosis, and stroke, progressive external ophthalmoplegia, myoclonic epilepsy with ragged red fibres, mitochondrial neurogastrointestinal encephalopathy syndrome, kearns–sayre syndrome, mitochondrial dna depletion syndrome, pearson syndrome, leigh syndrome, and neuropathy, ataxia, and retinitis pigmentosa. Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke segment is expected to command the largest market share of 17.1% in 2016 and is expected to reach USD 5.8 million by the end of 2020. This market is growing at a CAGR of 10.08% by the end of the forecast period 2017-2020.
On the basis of diagnostic test the global mitochondrial myopathy diagnosis and treatment market is segmented into genetic tests, muscle biopsy, and biochemical test. Genetic test segment is expected to command the largest market share of around 75% in 2016. This market is expected to reach USD 25.6 million in 2020 from USD 15.3 million in 2016, this market is expected to grow at a CAGR of 10.11% during the forecast period 2017-2020.
On the basis of therapy the global mitochondrial myopathy diagnosis and treatment market is segmented into supportive therapy and targeted therapy. Supportive therapy segment is expected to hold the 100% market share in 2016. Targeted therapy is projected to be the second-largest market in the coming future. This market is expected to reach USD 33.6 million in 2020 from USD 20.4 million in 2016, this market is expected to grow at a CAGR of 9.82% during the forecast period 2017-2020.
On the basis of region the global mitochondrial myopathy diagnosis and treatment market is segmented into Americas, Europe, Asia Pacific, and the Middle East & Africa. Americas region is expected to command a largest market share of 44% in 2016. This market is expected to reach USD 15 million in 2020 from USD 9 million in 2016, this market is growing at a CAGR of 10.8% during the forecast period 2017-2020.
Key Players
The leading market players in the global mitochondrial myopathy diagnosis and treatment market include AbbVie Inc (U.S.), Centogene AG (Germany), GeneDx (U.S.), Ixchel Pharma, Khondrion BV (The Netherlands), Mitobridge, Inc. (U.S.), NeuroVive Pharmaceutical AB (Sweden), Reata Pharmaceuticals Inc. (U.S.), Stealth Biotherapeutics (U.S.), and others.
Study objectives
• To provide detailed analysis of the market structure along with forecast of the various segments and sub-segments of the global mitochondrial myopathy diagnosis and treatment market
• To provide insights about factors influencing and affecting the market growth
• To provide historical and forecast revenue of the market segments and sub-segments with respect to countries
• To provide historical and forecast revenue of the market segments based on products, applications, and regions for the global mitochondrial myopathy diagnosis and treatment market.
• To provide strategic profiling of key players in the market, and comprehensively analysing their market share, core competencies, and drawing a competitive landscape for the market
• To provide economic factors that influences the global mitochondrial myopathy diagnosis and treatment market
• To provide detailed analysis of the value chain and supply chain of the global mitochondrial myopathy diagnosis and treatment market

Target Audience
• Global Mitochondrial myopathy diagnosis & treatment solutions, manufacturers & suppliers
• Research and development (R&D) companies
• Hospitals and clinics
• Academic institutes and universities
Key Findings
• The mitochondrial myopathy diagnosis and treatment global market and is expected to reach USD 33.6 million by 2020
• Mitochondrial encephalomyopathy, lactic acidosis, and stroke segment is expected to command the largest market share of around 17.1% in 2016.
• Americas region is expected to command a largest market share of 44% in 2016 and is expected to reach 15 million by the end of forecast period

The reports also covers regional analysis
• North America
o U.S.
o Canada
• Europe
o Germany
o France
o U.K
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Republic of Korea
o Rest of Asia-Pacific
• Middle East & Africa
o Middle East
o Africa

Table of Contents

1 Introduction 9
1.1 Definition 9
1.2 Scope of Study 9
1.3 Research Objective 9
1.4 Assumptions & Limitations 10
1.4.1 Assumptions 10
1.4.2 Limitations 10
1.5 Market Structure 11
2 Research Methodology 12
2.1 Research Process 12
2.2 Primary Research 13
2.3 Secondary Research 13
3 Market Dynamics 14
3.1 Introduction 14
3.2 Drivers 15
3.2.1 Rise in number of mitochondrial myopathy incidence rate and growing number of screening services. 15
3.2.2 Government funding and incentives for rare genetic diseases 15
3.3 Restraints 16
3.3.1 Poor treatment options and absence of curative treatment 16
3.3.2 Lack of awareness and diagnosis of the rare mitochondrial disorders 16
3.4 Opportunities 16
3.4.1 Faster market uptake and low marketing cost 16
3.4.2 Research and development 17
3.5 Challenges 17
3.5.1 Rare nature of the disease 17
3.5.2 Poor understanding of mitochondria and genetics 17
3.5.3 Cost of drug development and high investment risk 17
4 Market Factor Analysis 19
4.1 Porter’s Five Forces Analysis 19
4.1.1 Threat from a New Entrant 19
4.1.2 Bargaining Power of Buyer 20
4.1.3 Bargaining Power of Supplier 21
4.1.4 Threat from substitute 21
4.1.5 Intensity of Competitive Rivalry 21
4.2 Pipeline Analysis 23
4.2.1 Introduction 23
4.2.2 KH176 23
4.2.3 Elamipretide 24
4.2.4 RTA 408 25
4.2.5 IXC 103 26
4.2.6 NV556 26
4.3 Mega Trends 27
4.3.1 Strategies for increasing mitochondrial biogenesis 27
4.3.2 Antioxidant approaches 27
4.3.3 Targeting mitochondrial dynamics and biogenesis 28
4.3.4 Mitochondrial membrane lipids as therapeutic targets 28
4.3.5 Nucleoside replacement and gene therapy 28
4.3.6 Enzyme replacement therapy 28
4.4 Investment Opportunity Analysis 29
4.4.1 Market size (current and future), growth rate, and profitability 29
4.4.2 Investment Risks 29
4.4.3 Market Outlook 29
4.4.4 Competitors 30
4.4.5 Projections 30
5 Global Mitochondrial Myopathy Diagnosis & Treatment Market, By Type 31
5.1 Introduction 31
5.2 Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS) 31
5.3 Progressive External Ophthalmoplegia (PEO) 31
5.4 Myoclonic Epilepsy with Ragged Red Fibres (MERRF) 32
5.5 Mitochondrial Neurogastrointestinal Encephalopathy Syndrome (MNGIE) 32
5.6 Kearns–Sayre Syndrome (KSS) 32
5.7 Mitochondrial DNA Depletion Syndrome (MDS) 32
5.8 Pearson Syndrome 33
5.9 Leigh Syndrome 33
5.10 Neuropathy, Ataxia, and Retinitis Pigmentosa (NARP) 33
6 Global Mitochondrial Myopathy Diagnosis & Treatment Market, By Diagnostic Test 36
6.1 Introduction 36
6.2 Genetic Tests 36
6.3 Muscle Biopsy 36
6.4 Biochemical Test 37
7 Global Mitochondrial Myopathy Diagnosis & Treatment Market, By Therapy 39
7.1 Introduction 39
7.2 Supportive Therapy 39
7.3 Targeted Therapy 40
8 Global Mitochondrial Myopathy Diagnosis & Treatment Market, By Region 42
8.1 Introduction 42
8.2 Americas 44
8.3 Europe 45
8.4 Asia-Pacific 47
8.5 Middle East & Africa 48
9 Company Profile 49
9.1 AbbVie Inc. 49
9.1.1 Company Overview 49
9.1.2 Product Overview 49
9.1.3 Financial Overview 49
9.2 Centogene AG 51
9.2.1 Company Overview 51
9.2.2 Product Overview 51
9.2.3 Financial Overview 51
9.2.4 Key Development 51
9.3 GeneDx 52
9.3.1 Company Overview 52
9.3.2 Product Overview 52
9.3.3 Financial Overview 52
9.3.4 Key Development 52
9.4 Ixchel Pharma 53
9.4.1 Company Overview 53
9.4.2 Product Overview 53
9.4.3 Financial Overview 53
9.5 Khondrion BV 54
9.5.1 Company Overview 54
9.5.2 Product Overview 54
9.5.3 Financial Overview 54
9.5.4 Key Development 54
9.6 Mitobridge 55
9.6.1 Company Overview 55
9.6.2 Product Overview 55
9.6.3 Financial Overview 55
9.7 NeuroVive Pharmaceutical AB 56
9.7.1 Company Overview 56
9.7.2 Product Overview 56
9.7.3 Financial Overview 56
9.7.4 Key Development 57
9.8 Reata Pharmaceuticals Inc. 58
9.8.1 Company Overview 58
9.8.2 Product Overview 58
9.8.3 Financial Overview 58
9.9 Stealth Biotherapeutics 60
9.9.1 Company Overview 60
9.9.2 Product Overview 60
9.9.3 Financial Overview 60
9.9.4 Key Developments 60

The post Global Mitochondrial Myopathy Diagnosis & Treatment Market Analysis & Forecast 2017 To 2020 first appeared on CRI Report.